Related Experiment Video
Updated: Feb 26, 2026
Prediction of Red Blood Cell Antibody Significance Using the Monocyte-Macrophage Assay
Published on: February 7, 2025
Identification of Monocyte CD11c as a Potential Biomarker for Distinguishing Sepsis From Non-Infectious Inflammation
Limin Kong1, Yujun Zhou1, Dawei Li2
1Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Objective:
To investigate whether monocyte CD11c (mCD11c) can serve as a promising biomarker for the diagnosis and prognosis of sepsis, distinguishing it from non-infectious inflammatory conditions.
Methods:
A prospective, observational cohort study was conducted using a discovery cohort (sepsis, mild infection, patients after cardiovascular surgery, recovered sepsis patients, and healthy controls) and a validation cohort (sepsis, mild infection, and patients after cardiovascular surgery). Peripheral blood samples were analyzed using Cytometry by Time-of-Flight (CyTOF), single-cell RNA sequencing, and flow cytometry to assess the immune cell composition and mCD11c expression. Clinical data and outcomes were collected for analysis.
Results:
The discovery cohort showed a significant downregulation of mCD11c in patients with sepsis. The validation cohort confirmed a lower mCD11c% in sepsis than in the other groups. Receiver operating characteristic (ROC) curve analysis showed that mCD11c had a higher AUC (0.939, P < 0.001) than traditional markers in distinguishing sepsis from non-infectious inflammation. mCD11c% was an independent prognostic factor for 7-day mortality (P < 0.05), with significant differences in survival rates between patients with mCD11c% above and below 96.445%.
Conclusion:
mCD11c is a promising biomarker for early sepsis diagnosis and short-term survival prediction, outperforming the traditional markers. Larger multicenter studies are needed to validate these findings and to explore their potential as intervention targets.
